Literature DB >> 17852244

The Multiple Sclerosis impact Profile (MSIP). Development and testing psychometric properties of an ICF-based health measure.

Klaske Wynia1, Berrie Middel, Jitse P van Dijk, Han de Ruiter, Jacques de Keyser, Sijmen A Reijneveld.   

Abstract

PURPOSE: The aim of this study was to develop and test the structure of the Multiple Sclerosis Impact Profile (MSIP), and to evaluate its reliability and validity within a large group of MS patients.
METHOD: Data were obtained from a postal survey of 377 patients attending the Groningen MS centre of the university hospital and 153 patients from the MS patients' association.
RESULTS: Factor analysis showed that the MSIP comprised domains representing the four components of the International Classification (ICF). The body functions component comprised two factors, which we divided into three scales: 'muscles and muscle movement functions' (MMF), 'excretion and reproductive functions' (ERF) and 'mental functions' (MF). The activities component comprised one factor, which we divided into two scales: 'basic movement functions' (BMF) and 'activities of daily living' (ADL). The participation component comprised one factor: 'participation in life situations' (PLS). The environmental factors component comprised one factor: 'environmental factors' (EF). Four clinically relevant 'symptom' items were added to the questionnaire as single items. The MISP scales yielded sufficient to good internal consistency coefficients. Analysis of the convergent, divergent and known-groups validity indicated that the MSIP measures the physical, psychological and social impact of MS and discriminates between categories of course of disease and disease severity.
CONCLUSION: The MSIP seems to be a reliable and valid ICF-based outcome measure that covers a broad range of clinically relevant aspects of health. ICF can play an important role in measurement development and improvement of a unified and standard language in clinical practice and research.

Entities:  

Mesh:

Year:  2008        PMID: 17852244     DOI: 10.1080/09638280701256868

Source DB:  PubMed          Journal:  Disabil Rehabil        ISSN: 0963-8288            Impact factor:   3.033


  14 in total

Review 1.  Evolution of Patient-Reported Outcomes and Their Role in Multiple Sclerosis Clinical Trials.

Authors:  Cindy J Nowinski; Deborah M Miller; David Cella
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

2.  Design of a Randomised Controlled Trial (RCT) on the effectiveness of a Dutch patient advocacy case management intervention among severely disabled Multiple Sclerosis patients.

Authors:  Klaske Wynia; Coby Annema; Hans Nissen; Jacques De Keyser; Berrie Middel
Journal:  BMC Health Serv Res       Date:  2010-05-27       Impact factor: 2.655

3.  Validation of a Dutch version of the Actionable 8-item screening questionnaire for neurogenic bladder overactivity in multiple sclerosis: an observational web-based study.

Authors:  Peter Joseph Jongen; Bertil F M Blok; John P Heesakkers; Marco Heerings; Wim A Lemmens; Rogier Donders
Journal:  Health Qual Life Outcomes       Date:  2015-10-30       Impact factor: 3.186

4.  The interactive web-based program MSmonitor for self-management and multidisciplinary care in multiple sclerosis: concept, content, and pilot results.

Authors:  Peter Joseph Jongen; Ludovicus G Sinnige; Björn M van Geel; Freek Verheul; Wim I Verhagen; Ruud A van der Kruijk; Reinoud Haverkamp; Hans M Schrijver; J Coby Baart; Leo H Visser; Edo P Arnoldus; H Jacobus Gilhuis; Paul Pop; Monique Booy; Wim Lemmens; Rogier Donders; Anton Kool; Esther van Noort
Journal:  Patient Prefer Adherence       Date:  2015-12-11       Impact factor: 2.711

5.  Patient-reported adverse effects of high-dose intravenous methylprednisolone treatment: a prospective web-based multi-center study in multiple sclerosis patients with a relapse.

Authors:  Peter Joseph Jongen; Ioanna Stavrakaki; Bernard Voet; Erwin Hoogervorst; Erik van Munster; Wim H Linssen; Ludovicus G Sinnige; Wim I Verhagen; Leo H Visser; Ruud van der Kruijk; Freek Verheul; Jan Boringa; Marco Heerings; Werner Gladdines; Fredrik Lönnqvist; Pieter Gaillard
Journal:  J Neurol       Date:  2016-06-07       Impact factor: 4.849

6.  Beyond Disease: Happiness, Goals, and Meanings among Persons with Multiple Sclerosis and Their Caregivers.

Authors:  Antonella Delle Fave; Marta Bassi; Beatrice Allegri; Sabina Cilia; Monica Falautano; Benedetta Goretti; Monica Grobberio; Eleonora Minacapelli; Marianna Pattini; Erika Pietrolongo; Manuela Valsecchi; Maria Pia Amato; Alessandra Lugaresi; Francesco Patti
Journal:  Front Psychol       Date:  2017-12-20

7.  Stability and relative validity of the Neuromuscular Disease Impact Profile (NMDIP).

Authors:  Isaäc Bos; Jan B M Kuks; Josué Almansa; Hubertus P H Kremer; Klaske Wynia
Journal:  BMC Neurol       Date:  2017-05-11       Impact factor: 2.474

8.  Adherence to monthly online self-assessments for short-term monitoring: a 1-year study in relapsing-remitting multiple sclerosis patients after start of disease modifying treatment.

Authors:  Peter Joseph Jongen; Evert Sanders; Cees Zwanikken; Jan Koeman; Leo H Visser; Petra Koopmans; Dirk Lehnick
Journal:  Patient Prefer Adherence       Date:  2013-04-09       Impact factor: 2.711

9.  A prospective web-based patient-centred interactive study of long-term disabilities, disabilities perception and health-related quality of life in patients with multiple sclerosis in The Netherlands: the Dutch Multiple Sclerosis Study protocol.

Authors:  Peter Joseph Jongen; Marco Heerings; Wim A Lemmens; Rogier Donders; Anneke van der Zande; Esther van Noort; Anton Kool
Journal:  BMC Neurol       Date:  2015-08-04       Impact factor: 2.474

10.  The interactive web-based program MSmonitor for self-management and multidisciplinary care in multiple sclerosis: utilization and valuation by patients.

Authors:  Peter Joseph Jongen; Ludovicus G Sinnige; Björn M van Geel; Freek Verheul; Wim I Verhagen; Ruud A van der Kruijk; Reinoud Haverkamp; Hans M Schrijver; Jacoba C Baart; Leo H Visser; Edo P Arnoldus; Herman Jacobus Gilhuis; Paul Pop; Monique Booy; Marco Heerings; Anton Kool; Esther van Noort
Journal:  Patient Prefer Adherence       Date:  2016-03-03       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.